Bullock Wealth Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$164K Hold
2,268
– – 0.07% 191
2026
Q1
$113K Hold
2,268
– – 0.06% 207
2025
Q4
$66.9K Sell
2,268
-174
-7% -$4.73K 0.03% 231
2025
Q3
$67.4K Buy
2,442
+918
+60% +$25.6K 0.03% 238
2025
Q2
$43.7K Buy
1,524
+747
+96% +$19.7K 0.02% 254
2025
Q1
$21.1K Sell
777
-285
-27% -$10.1K 0.01% 303
2024
Q4
$44.2K Sell
1,062
-983
-48% -$47K 0.03% 263
2024
Q3
$131K Buy
2,045
+211
+12% +$19.4K 0.08% 176
2024
Q2
$213K Buy
1,834
+1,297
+242% +$164K 0.14% 130
2024
Q1
$56.7K Buy
+537
New +$54.1K 0.04% 235

Other funds holding MRNA

Bullock Wealth Management's MRNA Position: Q2 2026 in Review

Bullock Wealth Management held its Moderna (MRNA) position steady in Q2 2026 at 2,268 shares worth $164K. The position accounts for 0.07% of the portfolio, ranked #191.

Bullock Wealth Management first reported a position in MRNA in Q1 2024 and has held it in 10 quarters since. The position peaked at $213K in Q2 2024. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Bullock Wealth Management held 2,268 shares of Moderna worth $164K as of Q2 2026.
  • Bullock Wealth Management left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.07% of Bullock Wealth Management's portfolio in Q2 2026, its #191 holding.
  • Bullock Wealth Management first reported a position in Moderna in Q1 2024 and has held it in 10 quarters since.
  • Bullock Wealth Management's Moderna position peaked at $213K in Q2 2024.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Bullock Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.